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ABSTRACT
The antigen levels of components of the urokinase-type plasminogen
activator (uPA) system of plasminogen activation are correlated with
prognosis in several types of cancers, including breast cancer. In the
present study involving 2780 patients with primary invasive breast cancer,
we have evaluated the prognostic importance of the four major compo-
nents of the uPA system [uPA, the receptor uPAR (CD87), and the
inhibitors PAI-1 and PAI-2]. The antigen levels were determined by
ELISA in cytosols prepared from primary breast tumors. The levels of the
four factors significantly correlated with each other; the Spearman rank
correlation coefficients (rs) ranged from 0.32 (between PAI-2 and PAI-1 or
uPAR) to 0.59 (between uPA and PAI-1). The median duration of fol-
low-up of patients still alive was 88 months. In the multivariate analyses
for relapse-free survival (RFS) and overall survival (OS), we defined a
basic model including age, menopausal status, tumor size and grade,
lymph node status, adjuvant therapy, and steroid hormone receptor sta-
tus. uPA, uPAR, PAI-1, and PAI-2 were considered as categorical vari-
ables, each with two cut points that were established by isotonic regression
analysis. Compared with tumors with low levels, those with intermediate
and high levels showed a relative hazard rate (RHR) and 95% confidence
interval (95% CI) of 1.22 (1.02–1.45) and 1.69 (1.39–2.05) for uPA, and
1.32 (1.14–1.54) and 2.17 (1.74–2.70) for PAI-1, respectively, in multiva-
riate analysis for RFS in all patients. Compared with tumors with high
PAI-2 levels, those with intermediate and low levels showed a poor RFS
with a RHR (95% CI) of 1.30 (1.14–1.48) and 1.76 (1.38–2.24), respec-
tively. Similar results were obtained in the multivariate analysis for OS in
all patients. Furthermore, uPA and PAI-1 were independent predictive
factors of a poor RFS and OS in node-negative and node-positive patients.
PAI-2 also added to the multivariate models for RFS in node-negative and
node-positive patients, and in the analysis for OS in node-negative pa-
tients. uPAR did not further contribute to any of the multivariate models.
A prognostic score was calculated based on the estimates from the final
multivariate model for RFS. Using this score, the difference between the
highest and lowest 10% risk groups was 66% in the analysis for RFS at 10
years and 61% in the analysis for OS. Moreover, separate prognostic
scores were calculated for node-negative and node-positive patients. In the
10% highest risk groups, the proportion of disease-free patients was only
27 6 6% and 9 6 3% at 10 years for node-negative and node-positive
patients, respectively. These proportions were 86 6 4% and 61 6 6% for
the corresponding 10% lowest risk groups of relapse. We conclude that
several components of the uPA system are potential predictors of RFS and
OS in patients with primary invasive breast cancer. Knowledge of these
factors could be helpful to assess the individual risk of patients, to select
various types of adjuvant treatment and to identify patients who may
benefit from targeted therapies that are currently being developed.
INTRODUCTION
Cancer cell invasion and metastasis result from a coordinated interac-
tion between proteolytic enzymes degrading the ECM3 and the adhesive
proteins playing a role in cell attachment and migration. Data from
preclinical and clinical studies point toward a central role for the uPA
system in these processes (reviewed in Refs. 1–4). The serine protease
uPA, which binds to a specific cell surface receptor uPAR (5, 6), facil-
itates the conversion of plasminogen into the serine protease plasmin.
This wide-spectrum protease is able to degrade most components of the
ECM directly or indirectly through activation of metalloproteinases,
which subsequently degrade collagens and other matrix proteins (re-
viewed in Ref. 7). The activity of uPA can be inhibited by the serpin
inhibitors PAI-1 and PAI-2 (8). In addition, most components of the uPA
system of plasminogen activation have been linked to cell adhesion and
migration through both proteolytic and nonproteolytic mechanisms (re-
viewed in Refs. 1–3). Cell migration requires the interaction of cell-
bound adhesion receptors, such as integrins and uPAR, with their ECM-
associated ligands such as vitronectin (9–12). Binding of uPA, or
fragments of uPA containing only the receptor binding domain, enhance
binding of uPAR to vitronectin. PAI-1 can inhibit integrin and uPAR
binding to vitronectin, thus directing a stepwise cell migration by allow-
ing tumor cells to be attached or alternatively being detached from the
ECM (10, 11, 13, 14).
Duffy et al. (15) were the first to link increased levels of uPA
activity in breast tumor extracts with a high rate of relapse in patients
with breast cancer. This important finding of an association between
uPA and a poor prognosis has been confirmed by various research
groups measuring uPA antigen levels (16) in breast tumors, as well as
in a variety of other cancer types (reviewed in Refs. 4, 17). Interest-
ingly, immunocytologically detected uPA-positive tumor cells in bone
marrow from primary breast cancer patients were predictive of a poor
prognosis (18). Moreover, as reported by Ja¨nicke et al. (19), surpris-
ingly at first, increased levels of the inhibitor PAI-1 were associated
with a poor prognosis in primary breast cancer (4, 17), and like uPA,
also in recurrent breast cancer treated with tamoxifen (20). These
findings can now partly be explained by the recently ascribed role of
PAI-1 in tumor cell adhesion and migration (1–3). As would be
expected, high tumor levels of uPAR were associated with a poor
prognosis (21, 22), and high levels of PAI-2 were associated with a
favorable prognosis in patients with breast cancer (23, 24).
Because simultaneous measurement of the different components of
the uPA system of plasminogen activation may provide more power-
ful prognostic information, we determined the levels of uPA, uPAR,
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PAI-1, and PAI-2 in breast tumors of 2780 patients and have corre-
lated their levels with RFS and OS.
MATERIALS AND METHODS
Patients and Tissues. Analysis of RFS and OS was performed in 2780
patients with primary, operable, invasive breast cancer. The selection of
samples was based on the availability of 3486 stored cytosol extracts (in liquid
nitrogen), which remained after routine ER and PgR analysis. Exclusion
criteria were: patient tissue that was taken from a biopsy only (such as
inoperable T4 tumors or tissue that was not obtained from the primary breast
tumor); previous diagnosis of carcinoma, with the exception of basal skin
carcinoma and cervical cancer stage I; metastatic disease at diagnosis (M1
patients) or evidence of disease within 1 month of primary surgery; neoadju-
vant therapy; and insufficient follow-up documentation. In the case of mas-
tectomy after an initial lumpectomy because of residual disease, mastectomy is
considered the primary treatment. Median age of the patients at surgery
(modified mastectomy, 1488 patients; breast conserving treatment, 1292 pa-
tients) was 57 years (range, 22–94 years). Radiotherapy was given to 75% of
the patients: on the breast/thoracic wall in 1762 patients and/or on the axilla in
747 patients; and/or parasternal and/or supraclavicular lymph nodes in 873
patients. None of the 1405 node-negative patients received systemic adjuvant
therapy. Of the 1375 node-positive patients, adjuvant chemotherapy (mainly
cyclophosphamide/methotrexate/5-fluorouracil) was given to 446 patients
(mainly premenopausal patients), whereas 208 patients received adjuvant
hormonal therapy (mainly postmenopausal patients), either alone (185 pa-
tients) or in combination with chemotherapy (23 patients). All patients were
examined routinely every 3–6 months during the first 5 years of follow-up and
once a year thereafter. Of the 2780 patients included, 1297 patients (47%)
showed evidence of disease during follow-up and count as failures in the
analysis for RFS. One-hundred and seventy-two patients (6%) died without
evidence of disease and were censored at last follow-up in the analysis of RFS.
Nine-hundred and twelve patients (33%) died after a previous relapse. A total
of 1084 (172 1 912) patients (39%) were failures in the analysis for OS. The
median follow-up period of patients alive (n 5 1,696) was 88 months (range,
1–207 months). Further characteristics of patients and tumors are listed in
Table 1.
Assay of uPA, uPAR, PAI-1, PAI-2, ER, and PgR in Tumor Tissue
Extracts. Tumor tissues were stored in liquid nitrogen and pulverized in
the frozen state with a microdismembrator as recommended by the Euro-
pean Organization for Research and Treatment of Cancer for processing of
breast tumor tissue for cytosolic ER and PgR determinations (25). The
resulting tissue powder was suspended in European Organization for Re-
search and Treatment of Cancer receptor buffer (10 mM K2HPO4, contain-
ing 1.5 mM dipotassium chloride EDTA, 3 mM NaN3, 10 mM monothio-
glycerol, and 10% v/v glycerol, pH 7.4). The suspension was centrifuged
for 30 min at 100,000 3 g at 4°C to obtain the supernatant fraction
(cytosol). ER and PgR levels were determined by ligand binding assay or
enzyme immunoassay, as described before (26).
uPA, uPAR, PAI-1, and PAI-2 levels were determined in breast tumor
cytosols with ELISAs. For uPA and PAI-1, ELISA (27, 28) reagents have been
used that are commercially available in assay kits (American Diagnostica,
Greenwich, CT). The details of the assay procedures, including those of the
specificity and performance of the uPAR and PAI-2 ELISAs, have been
described elsewhere (22, 24, 29). To enable the assessment of the between-
assay variations (% CV), in each assay-run an aliquot of a pooled breast cancer
cytosol sample was analyzed. The between-assay CV was 12.7, 21.2, 14.3, and
8.4% for the uPA, uPAR, PAI-1, and PAI-2 assays, respectively. The within-
Table 1 Relationships of uPA, uPAR, PAI-1, and PAI-2 with patient and tumor characteristics
Characteristic Frequencyb
Median value (interquartile range)a
uPA uPAR PAI-1 PAI-2
All patients 2780 0.75 (0.28–1.49)c 0.94 (0.59–1.38)c 15.2 (8.4–25.3)c 2.35 (1.32–4.72)c
Age at surgery (yr)
#40 324 0.76 (0.34–1.38) 1.00 (0.67–1.51) 15.5 (8.3–25.3) 1.98 (1.18–4.23)
41–55 998 0.76 (0.28–1.47) 0.95 (0.59–1.39) 13.8 (7.6–23.1) 2.00 (1.12–3.90)
56–70 943 0.79 (0.28–1.57) 0.95 (0.61–1.35) 15.4 (8.7–26.5) 2.64 (1.42–5.52)
.70 515 0.64 (0.26–1.41) 0.85 (0.54–1.28) 16.5 (9.0–27.5) 2.84 (1.65–5.90)
P 0.16d ,0.0005e ,0.001d ,0.0001e
Menopausal status
Premenopausal 1107 0.77 (0.29–1.44) 0.96 (0.62–1.42) 14.2 (7.9–23.2) 1.95 (1.12–3.80)
Postmenopausal 1673 0.73 (0.27–1.51) 0.94 (0.58–1.35) 15.7 (8.8–26.7) 2.68 (1.47–5.62)
P 0.92f 0.04f 0.0002f ,0.0001f
Tumor size
T1 1184 0.73 (0.24–1.41) 0.92 (0.57–1.31) 13.5 (7.8–23.0) 2.49 (1.37–5.31)
T2 1334 0.80 (0.32–1.58) 0.96 (0.61–1.43) 16.2 (8.9–26.8) 2.31 (1.33–4.38)
T3/4 262 0.62 (0.24–1.29) 0.97 (0.59–1.57) 15.2 (8.7–25.3) 1.96 (1.09–3.58)
P ,0.001d ,0.005e 0.0001d ,0.001e
Nodal status
N0 1405 0.73 (0.24–1.43) 0.91 (0.56–1.33) 14.3 (7.8–23.4) 2.47 (1.39–5.01)
N1–3 725 0.76 (0.30–1.49) 0.96 (0.66–1.40) 15.3 (8.6–25.8) 2.47 (1.36–5.03)
N.3 650 0.77 (0.31–1.57) 0.97 (0.62–1.48) 16.5 (9.2–27.0) 2.02 (1.12–3.71)
P 0.11e ,0.005e ,0.0001e ,0.0001d
Grade
Well 43 0.24 (0.11–0.75) 0.66 (0.38–1.02) 8.6 (3.7–13.3) 1.87 (1.24–4.90)
Moderate 530 0.81 (0.32–1.42) 0.98 (0.64–1.36) 15.0 (8.6–24.1) 2.73 (1.45–6.69)
Poor 1540 0.78 (0.29–1.57) 0.96 (0.61–1.42) 15.8 (9.0–26.3) 2.33 (1.32–4.53)
P 0.0002d 0.005d ,0.0002e ,0.0005d
ER positiveg
No 602 0.99 (0.40–1.78) 1.21 (0.75–1.81) 17.5 (9.3–31.3) 2.82 (1.59–6.14)
Yes 2102 0.66 (0.24–1.39) 0.91 (0.57–1.26) 14.4 (8.2–24.2) 2.21 (1.26–4.39)
P ,0.0001f ,0.0001f ,0.0001f ,0.0001f
PgR positiveg
No 794 0.92 (0.35–1.77) 1.04 (0.62–1.62) 17.3 (9.4–30.6) 2.63 (1.45–5.46)
Yes 1866 0.66 (0.24–1.37) 0.92 (0.58–1.28) 14.1 (8.0–23.7) 2.24 (1.26–4.57)
P ,0.0001f ,0.0001f ,0.0001f 0.0002f
a All values in ng/mg protein.
b Because of unknown values, the numbers do not always add up to 2780.
c The full range in ng/mg of protein were: 0–24.4 for uPA; 0–37.0 for uPAR; 0–479 for PAI-1; and 0–829 for PAI-2.
d P for Kruskal-Wallis test.
e P for Wilcoxon-type test for trend.
f P for Wilcoxon Rank-Sum test.
g Cutoff point used for ER and PgR: 10 fmol/mg of protein.
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assay CVs of samples measured in duplicate were all ,5%. During the period
of the assays (.3 years), there was no significant change in the levels of any
of the four factors in the breast cancer cytosol pool. These results suggest that
the factors were stable during long-term storage of the cytosols.
Statistics. The strength of the associations between uPA, uPAR, PAI-1,
and PAI-2 was tested with Spearman rank correlation (rs). The associations of
these factors with other variables were tested with the nonparametric Wilcoxon
Rank-Sum test or Kruskal-Wallis test, followed by a Wilcoxon-type test for
trend across ordered groups where appropriate. RFS and OS probabilities were
calculated by the actuarial method of Kaplan and Meier (30). In our search for
the best categorization of uPA, uPAR, and PAI-1, we have used IRA using
RFS as end point (28, 31). After it had been established that in a test for trend
using log-transformed variables increasing levels were significantly associated
with RFS, an IRA was performed after correction for age/menopausal status,
tumor size and grade, lymph node status, adjuvant therapy, and ER and PgR
status. These factors defined the basic multivariate model for all patients that
we incorporated in our analyses. Increasing PAI-2 levels were significantly
associated with a favorable prognosis, however, only when uPA was also
added to the basic multivariate model. For node-positive patients, nodal status
was included as N.3 versus N1–3, and for node-negative patients, nodal status
and adjuvant therapy were not applicable. The univariate and multivariate
analyses, including tests for interactions, were performed using the Cox
proportional hazards model (32). The assumption of proportional hazards was
verified graphically. The associated likelihood ratio test was used to test for
differences between models with variables included and excluded. In the
multivariate analyses, the missing values for ER (n 5 76), PgR (n 5 120), and
tumor grade (n 5 677) were treated as separate groups to allow inclusion of all
patients in all models. The results from Cox analyses, including the basic
model and the components of the uPA system that significantly added to the
model, were used to classify patients into risk groups using as cut points the 10,
25, 50, 75, and 90 percentiles of the calculated linear score from the Cox
analyses. The resulting risk groups are visualized by Kaplan-Meier curves. All
computations were done with the STATA statistical package, release 6.0
(STATA Corp., College Station, TX). All Ps are two-sided and relate to all
available data during the total period of follow-up.
RESULTS
Levels and Associations. Levels of uPA, uPAR, PAI-1, and PAI-2
expressed as ng/mg of protein were measured in cytosols of primary
breast tumors using specific ELISAs. The levels determined in 2780
patients (Table 1) are comparable with those obtained previously in
fewer patients, with reported median levels in ng/mg of protein of 0.7
for uPA (27), 0.87 for uPAR (22), 15.2 for PAI-1 (28), and 2.26 for
PAI-2 (24). For all four variables, the distribution was approximately
log normal.
The Spearman rank correlation coefficients (rs) between the various
factors of the uPA system varied from rs 5 0.32 (between PAI-2 and
PAI-1 or uPAR) to rs 5 0.59 (between uPA and PAI-1). Table 1
shows their relationships with patient and tumor characteristics. Lev-
els of all four parameters were higher in ER- or PgR-negative tumors
as compared with hormone receptor-positive tumors. The levels of
uPA were not significantly related with age, menopausal status, or
lymph node status. Well-differentiated and T3/4 tumors had the lowest
Table 2 Cox multivariate analysis of RFS and OS in 2780 patients
Factor
RFS OS
RHRa P RHRa P
Basic model
Age and menopausal statusb ,0.0001 ,0.0001
Age premenopausalc 0.68 (0.60–0.77) 0.75 (0.65–0.88)
Age postmenopausalc 0.94 (0.84–1.00) 1.24 (1.13–1.35)
Post- vs. premenopausal 1.43 (1.16–1.77) 1.35 (1.05–1.74)
Tumor size ,0.0001 ,0.0001
2–5 cm vs. #2 cm 1.43 (1.26–1.62) 1.45 (1.26–1.67)
.5 cm vs. #2 cm 1.85 (1.53–2.24) 1.87 (1.53–2.29)
Nodal status ,0.0001 ,0.0001
N1–3 vs. N0 2.02 (1.72–2.37) 2.08 (1.75–2.47)
N.3 vs. N0 3.75 (3.22–4.36) 3.53 (2.99–4.17)
Grade ,0.0001 ,0.005
Moderate vs. poor 0.72 (0.62–0.85) 0.74 (0.62–0.88)
Well vs. poor 0.61 (0.34–1.08) 0.65 (0.36–1.19)
Missing vs. poor 0.73 (0.56–0.96) 0.91 (0.78–1.05)
Adjuvant therapy (yes vs. no) 0.61 (0.52–0.71) ,0.0001 0.76 (0.64–0.89) ,0.001
ER/PgR statusd 0.42 ,0.0001
1/2 vs. 2/2 0.97 (0.79–1.19) 0.82 (0.66–1.01)
2/1 vs. 2/2 0.81 (0.61–1.08) 0.63 (0.46–0.86)
1/1 vs. 2/2 0.91 (0.79–1.06) 0.63 (0.54–0.74)
Missing vs. 2/2 0.80 (0.58–1.10) 0.65 (0.47–0.90)
Additions to basic model:
1uPAe,f ,0.0001 ,0.0001
Intermediate vs. low 1.29 (1.10–1.52) 1.37 (1.15–1.64)
High vs. low 1.93 (1.64–2.28) 2.15 (1.79–2.59)
1uPARe,g ,0.0001 ,0.0001
Intermediate vs. low 1.10 (0.95–1.28) 1.01 (0.85–1.19)
High vs. low 1.36 (1.17–1.59) 1.32 (1.12–1.56)
1PAI-1e,h ,0.0001 ,0.0001
Intermediate vs. low 1.50 (1.31–1.71) 1.43 (1.23–1.66)
High vs. low 2.52 (2.06–3.08) 2.64 (2.13–3.26)
1PAI-2e,i 0.10 0.99
Intermediate vs. high 1.12 (0.99–1.27) 1.00 (0.88–1.15)
Low vs. high 1.24 (0.99–1.57) 0.99 (0.76–1.29)
a Numbers in parentheses, 95% CI.
b Age and menopausal status (at surgery) combined.
c Age in decades tested separately for pre- and postmenopausal patients.
d Cut points used: 10 fmol/mg of protein for both.
e Added separately to the basic multivariate model.
f Low, #0.19 (n 5 560); intermediate, .0.19 and #1.21 (n 5 1313); high, .1.21 ng/mg of protein (n 5 907).
g Low, #0.57 (n 5 663); intermediate, .0.57 and #1.13 (n 5 1100); high, .1.13 ng/mg of protein (n 5 1017).
h Low, #9.33 (n 5 815; intermediate, .9.33 and #45.28 (n 5 1731); high, .45.28 ng/mg of protein (n 5 229).
i Low, #0.62 (n 5 165); intermediate, .0.62 and #4.05 (n 5 1804); high, .4.05 ng/mg of protein (n 5 811).
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uPA levels, whereas moderately differentiated and T2 tumors had the
highest levels. In general, uPAR followed the same pattern of distri-
bution over the various patient groups, and all of the relationships
were statistically significant, i.e., the negative relationships of uPAR
with age and menopausal status, and the positive associations between
uPAR and tumor size and nodal status (Table 1). As was also observed
for uPA, the highest uPAR and PAI-2 levels were found in moderately
differentiated tumors. PAI-1 showed a positive relationship with tu-
mor size, nodal status, tumor grade, age, and menopausal status.
PAI-2 showed positive relationships with age and menopausal status,
and negative relationships with nodal status and tumor size (Table 1).
Multivariate Analysis. To study which factors of the urokinase
system add significantly to the prognostic information already pro-
vided by traditional prognostic factors, we first designed a basic
multivariate model for all patients (Table 2). This model, which
included age, menopausal status, tumor size and grade, the number of
positive lymph nodes, adjuvant therapy, and ER/PgR status, was
significantly associated with RFS (x2 5 517; df 5 15; P , 0.0001)
and OS (x2 5 519; df 5 15; P , 0.0001). For both uPAR and PAI-2,
the results of the IRA, after correction for the basic multivariate
model, suggested that these variables could be considered as categor-
ical variables with two cut points. The cut points chosen were 0.57
and 1.13 ng/mg of protein for uPAR and 0.62 and 4.05 ng/mg of
protein for PAI-2. On the other hand, for uPA and PAI-1 the results
were less clear and did not reveal a clear indication for cut points.
However, to enable visualization of their relationships with RFS and
for reasons of uniformity with the analyses of uPAR and PAI-2, we
categorized uPA and PAI-1 at the levels of the two largest steps in the
IRA. These levels were 0.19 and 1.21 ng/mg protein for uPA and 9.33
and 45.28 ng/mg protein for PAI-1. When each variable was added
separately to the basic model for RFS, the addition of uPA resulted in
a Dx2 of 73.6 (df 5 2), a Dx2 of 19.9 (df 5 2) for uPAR, a Dx2 of 81.4
(df 5 2) for PAI-1, and a Dx2 of 4.6 (df 5 2) for PAI-2. The RHRs
and their 95% CI from the Cox multivariate analysis are listed in
Table 2. High levels of uPA, uPAR, or PAI-1 were significantly
associated with an early relapse, whereas PAI-2 did not significantly
contribute to the basic multivariate model. Similar results were ob-
tained in the analyses for OS (Table 2). The Kaplan-Meier curves for
RFS as a function of the levels of uPA, uPAR, PAI-1, and PAI-2 are
shown in Fig. 1. There were no statistically significant interactions
between any of the prognostic variables in multivariate analysis for
RFS or OS. Separate Cox multivariate analyses for RFS and OS were
subsequently performed to establish whether combinations of uPA,
uPAR, PAI-1, and PAI-2 would increase the prognostic strength of the
classical prognostic factors already included in the basic model. When
the four factors of the uPA system were added as log-transformed
continuous variables to the basic model for RFS in all patients, high
levels of uPA and PAI-1 were associated with a poor prognosis,
whereas high levels of PAI-2 were associated with a favorable prog-
nosis in the final model for RFS (for all, P , 0.001). The RHRs and
95% CIs for the components of the uPA system that are included as
categorical variables in the final model for all patients and in sub-
groups of node-negative and node-positive patients are shown in
Table 3. uPAR did not contribute to any of the models. Only in the
analysis for OS in node-positive patients did PAI-2 not appear to be
an independent prognostic variable. In all other analyses, uPA, PAI-1,
and PAI-2 significantly added to the prognostic strength provided by
the classical prognostic factors included in the basic model (Table 3).
The increase in x2 caused by the addition of uPA, PAI-1, and PAI-2
to the basic model was 136 (df 5 6) in the analysis for RFS and 120
in the analysis for OS. In node-negative patients with a x2 of 76
(df 5 12) for the model including age and menopausal status, tumor
size and grade, and ER/PgR status, the Dx2 as a result of the addition
of uPA, PAI-1, and PAI-2 was 71 (df 5 6) in analysis for RFS, and
Fig. 1. RFS according to uPA, uPAR, PAI-1, or PAI-2 in all 2780 patients. A, RFS as a function of uPA values; B, RFS as a function of uPAR values; C, RFS as a function of
PAI-1 values; D, RFS as a function of PAI-2 values. Numbers in parentheses refer to the number of failures/total number of patients per group. L, low values; I, intermediate values;
H, high levels, of the respective variable. For cut points, see the legend to Table 2.
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in the analysis for OS, the x2 increased from 82 to 133 by the addition
of the three factors. In node-positive patients, the x2 increased from
221 (df 5 14) for the model including age and menopausal status,
tumor size and grade, the number of positive lymph nodes, adjuvant
therapy, and ER/PgR status to 295 in the analysis for RFS, and from
207 to 297 in the analysis for OS.
Prognostic Scores. In further analyses, we established prognostic
scores based on the regression coefficients of the variables included in
the final Cox multivariate models for all patients and separately for
node-negative and node-positive patients. Kaplan-Meier curves were
constructed for patients with the 10% lowest risk (group a), between
10% and 25% (group b), between 25% and 50% (group c), between
50% and 75% (group d), between 75% and 90% (group e), and the
10% highest risk for failure (group f). The actuarial RFS curve for all
patients as a function of the prognostic score shows a significant
separation for the different groups. At 10 years of follow-up, the
difference between patients in the 10% highest and lowest risk groups
was 66% in analysis for RFS (Fig. 2A) and 61% in analysis for OS
(Fig. 2B).
The actuarial RFS curves as a function of the prognostic score for
node-negative and node-positive patients are shown in Fig. 3, A and B,
respectively. For node-negative patients, at 10 years the difference
between the 10% lowest risk group (86 6 4% relapse free) and the
10% highest risk group (27 6 6% relapse free) was 59%. For
node-positive patients, at 10 years the difference in RFS between the
two extreme groups was 52% (61 6 6% and 9 6 3% for the 10%
lowest and highest risk groups, respectively).
DISCUSSION
Determination of the tumor antigen levels of components of the
uPA system may help to predict the time to disease recurrence and the
overall survival rate in patients with primary breast cancer. This is of
particular importance for patients with node-negative disease, who as
a group have a relatively favorable prognosis. The goal of the present
investigation was to evaluate a possible combined prognostic value of
the four major components of the uPA system of plasminogen acti-
vation, uPA, uPAR, PAI-1, and PAI-2, in patients with primary
invasive breast cancer.
Immunohistochemistry and in situ hybridization on breast cancer
tissues showed that uPA, uPAR, PAI-1, and/or PAI-2 are expressed
and synthesized by both tumor cells and host cells, including
(myo)fibroblasts, endothelial cells, and phagocytic cells (reviewed in
Refs. 1 and 4). A differential expression of the four components by the
various cell types and an interplay between these cells may be nec-
essary for the function of the system in various cellular processes at
different stages of tumor progression (1). It has been shown that, in
general, elevated antigen levels of uPA, uPAR, and PAI-1 determined
in tumor extracts are associated with poor prognosis in a variety of
cancer types. In contrast, increased PAI-2 antigen levels are associ-
ated with a favorable prognosis (reviewed in Refs. 1, 4, and 17). The
association of a high tumor level of PAI-1 with a poor prognosis in
patients with primary breast cancer (19) has been explained by its
inhibition of uPA activity and thus preventing degradation of tumor
stroma, allowing new ECM to be formed (33), but it can also be
attributed to its recently ascribed role in tumor cell adhesion and
migration (10, 11, 13, 14). Furthermore, PAI-1 has been shown to be
involved in uPAR clearance from the cell surface by promoting
internalization of the formed ternary uPA:uPAR:PAI-1 complex (3,
34). Besides its antiproteolytic function, PAI-1 is necessary for focal-
ized and optimal invasiveness (35), associated with angiogenic activ-
ity (36), and is essential for tumor cell invasion and tumor vascular-
ization in PAI-1-deficient mice (37). Together these observations
strongly imply that PAI-1 plays a primary role in tumor progression.
Because we showed previously that the uPAR level in the cytosol was
Table 3 Cox multivariate analysis in all patients and in nodal subgroups of patients
Factora
RFS OS
RHRb P RHRb P
All patients:
1uPA ,0.0001 ,0.0001
Intermediate vs. low 1.22 (1.02–1.45) 1.32 (1.08–1.61)
High vs. low 1.69 (1.39–2.05) 1.92 (1.54–2.38)
1PAI-1 ,0.0001 ,0.0001
Intermediate vs. low 1.32 (1.14–1.54) 1.18 (0.99–1.40)
High vs. low 2.17 (1.74–2.70) 2.00 (1.58–2.55)
1PAI-2 ,0.0001 0.02
Intermediate vs. high 1.30 (1.14–1.48) 1.16 (1.01–1.33)
Low vs. high 1.76 (1.38–2.24) 1.43 (1.09–1.89)
Node-negative patients:
1uPA ,0.0001 ,0.0001
Intermediate vs. low 1.31 (0.98–1.76) 1.46 (1.03–2.07)
High vs. low 2.02 (1.47–2.77) 2.45 (1.67–3.59)
1PAI-1 ,0.002 0.003
Intermediate vs. low 1.34 (1.04–1.73) 1.09 (0.81–1.47)
High vs. low 2.03 (1.39–2.97) 1.71 (1.13–2.61)
1PAI-2 ,0.0001 ,0.05
Intermediate vs. high 1.45 (1.17–1.81) 1.19 (0.93–1.52)
Low vs. high 2.57 (1.71–3.86) 1.89 (1.16–3.10)
Node-positive patients:
1uPA ,0.001 ,0.0001
Intermediate vs. low 1.18 (0.94–1.47) 1.27 (1.00–1.61)
High vs. low 1.52 (1.19–1.94) 1.72 (1.32–2.24)
1PAI-1 ,0.0001 ,0.0001
Intermediate vs. low 1.34 (1.11–1.63) 1.23 (1.00–1.52)
High vs. low 2.26 (1.72–2.98) 2.13 (1.59–2.86)
1PAI-2 ,0.002 0.20
Intermediate vs. high 1.23 (1.04–1.45) 1.15 (0.97–1.36)
Low vs. high 1.47 (1.09–1.99) 1.26 (0.90–1.75)
a Low, intermediate, and high for the respective factors; see legend to Table 2.
b Numbers in parentheses, 95% CI; corrected for the basic model including age and menopausal status, tumor size and grade, nodal status, adjuvant therapy, and ER/PgR status.
For node-positive patients, nodal status was included as N.3 vs. N1–3; for node-negative patients, nodal status and adjuvant therapy were not applicable.
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a much stronger prognostic factor than the uPAR level in the detergent
extract, which also contains plasma membrane components (22),
uPAR was measured only in the cytosols in the present study. The
higher prognostic value of uPAR in cytosols was explained by its
presentation as a water-soluble degradation product that has lost its
lipid anchor because of the action of either proteases or phospho-
lipases. The soluble uPAR may have been formed as a result of
plasmin generation, which on cell surfaces happens in close vicinity to
uPAR (38). Such a soluble form of uPAR has been detected in ascites
fluid from patients with ovarian cancer (39). It was also found to be
elevated in the blood of cancer patients (40, 41) and patients with
paroxysmal nocturnal hemoglobinuria (42), when compared with
healthy controls. Recently, high plasma levels of soluble uPAR were
found to be correlated with a poor prognosis in patients with colorec-
tal cancer (43).
We showed that the interrelationships between uPA, uPAR, PAI-1,
and PAI-2 were all positive and statistically significant, with Spear-
man correlations ranging from 0.32 to 0.59. Similar positive relation-
ships between two or more of these factors have been reported before
(21–22, 24, 28, 44–46). In the present study, all four variables were
negatively related with ER and PgR. The levels of uPA were in
general not significantly related with poor prognostic characteristics.
However, the levels of uPAR and PAI-1 were in most analyses
weakly, although significantly, associated with poor prognostic fea-
tures, whereas PAI-2 levels were associated with favorable prognostic
characteristics. Because most relationships were weak yet statistically
significant, probably as a result of the large numbers included, several
of the observed associations may hardly be of biological relevance.
With respect to prognosis, we show that high tumor levels of uPA,
uPAR, and PAI-1 were associated with poor, and of PAI-2 with a
favorable, RFS and OS for patients with primary breast cancer.
Moreover, when added separately to the basic multivariate model
including traditional prognostic factors, uPA, uPAR, and PAI-1 all
gave additional prognostic information. PAI-1 appeared to be the
second strongest prognostic factor after nodal status, superior to the
established factors such as tumor size (Table 2). In contrast, PAI-2
levels were not significantly associated with prognosis in multivariate
analysis when corrected for the contribution of traditional prognostic
factors. PAI-2 was significantly associated with a favorable prognosis
when added to the multivariate models together with uPA and PAI-1.
This may seem odd, however, we have shown before that PAI-2 was
only of prognostic value in tumors with high levels of uPA and not in
those with low uPA levels (24). This phenomenon of PAI-2 being an
independent favorable prognostic factor in the presence of uPA could
be attributable to the positive association between the levels of PAI-2
and the other three components of the uPA system that are related to
a poor prognosis. When combining the various factors of the uroki-
nase system in multivariate analyses for RFS and OS, uPAR did not
Fig. 2. RFS and OS according to prognostic score in all 2780 patients. A, RFS and B,
OS, as a function of the total prognostic score, which was derived from the estimates of
the coefficients of the variables from the Cox multivariate analysis for RFS. Included in
the multivariate analysis were: age premenopausal (in decades), age postmenopausal (in
decades), postmenopausal status (post- versus premenopausal), lymph node status (N1–3
versus N0, N.3 versus N0), tumor size (T2 versus T1, T3/4 versus T1), tumor grade (well
versus poor, moderate versus poor, missing versus poor), ER/PgR status (2/1 versus
2/2, 1/2 versus 2/2, 1/1 versus 2/2, missing versus 2/2), adjuvant therapy (yes
versus no), uPA (.0.19–1.21 ng/mg of protein versus #0.19 ng/mg of protein, .1.21
ng/mg of protein versus #0.19 ng/mg of protein), PAI-1 (.9.33–45.28 ng/mg of protein
versus #9.33 ng/mg of protein, .45.28 ng/mg of protein versus #9.33 ng/mg of protein),
and PAI-2 (.0.62–4.05 ng/mg of protein versus #0.62 ng/mg of protein, .4.05 ng/mg
of protein versus #0.62 ng/mg of protein). a, the lowest 10% risk group of patients; b, the
10–25% risk group; c, the 25–50% risk group; d, the 50–75% risk group; e, the 75–90%
risk group; and f, the .90% risk group. Numbers in parentheses refer to the number of
failures/total number of patients per group.
Fig. 3. RFS according to prognostic score in node-negative and node-positive patients.
A, RFS in node-negative patients, and B, in node-positive patients, as a function of the
prognostic score based on variables comprising the basic model and uPA, PAI-1, and
PAI-2. The prognostic score was derived from the estimates of the coefficients of the
variables of the basic model and those of uPA, PAI-1, and PAI-2, from Cox multivariate
analyses for RFS in node-negative and node-positive patients, respectively (see Table 3).
uPA, PAI-1, and PAI-2, were included as categorical variables as described in the legend
to Fig. 2. a, the lowest 10% risk group of patients; b, the 10–25% risk group; c, the
25–50% risk group; d, the 50–75% risk group; e, the 75–90% risk group; and f, the .90%
risk group. Numbers in parentheses refer to the number of failures/total number of patients
per group.
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further contribute to the models in which uPA and/or PAI-1 were
included.
It has been argued recently by Powles (47) that “the time has come
to individualize adjuvant chemotherapy, basing it more on the bio-
logical characteristics of individual tumors rather than on the wide-
spread treatment of large groups of patients.” In this line of thought,
we aimed to establish a prognostic score based on the contribution of
various traditional and tumor cell biological prognostic factors. Using
a score based on the traditional prognostic variables and the inde-
pendent biological variables uPA, PAI-1, and PAI-2, we were able to
obtain survival curves that showed a wide separation between patients
in the various risk groups of patients, as well as in nodal subgroups of
patients. It should, however, be emphasized that the largest power of
the models in all patients are derived from the classical prognostic
factors, particularly nodal status and tumor size. In analysis for RFS
in all patients, the x2 of the basic model containing the classical
prognostic factors was 517 (df 5 15). The independent biological
factors uPA, PAI-1, and PAI-2 only added moderately to this model
(increase in x2 of 136, df 5 6). Importantly, for node-negative
patients, this increase in x2 caused by the addition of the three factors
was 71 (df 5 6). This is relatively high compared with the x2 of 76
(df 5 12) already provided by the classical prognostic factors.
In the present study, the levels of the components of the urokinase
system of plasminogen activation were determined with specific
ELISAs performed on tumor extracts, which does not discriminate
between the cell type that expresses the specific factor. Nevertheless,
the measured levels correlated with prognosis in several cancer types
in many published studies. An advantage of using ELISAs is that the
assays can easily be subjected to external quality control programs
(48). With respect to immunohistochemical assessment of the com-
ponents of the uPA system, discrepant results on the localization of
the different factors have been published by various groups. It has
been argued by Andreasen et al. (1) that to ascertain the specificity of
immunohistochemical stainings and to obtain conclusive results, spe-
cial care should be taken regarding a number of control experiments
and that, although immunohistochemical studies may reveal where the
various components are present, the localization of the active com-
ponents remains elusive (1).
Several of the components of the uPA system are potential targets
for antiangiogenic, anti-invasive, and/or antimetastatic therapy, and
various different approaches to interfere with the expression or reac-
tivity of uPA or uPAR at the gene or protein level have been proven
successful. Such therapeutic approaches include the application of
antisense oligonucleotides, antibodies, enzyme inhibitors, and recom-
binant and synthetic uPA and uPAR analogues (reviewed in Refs. 1,
3, and 4). Because the uPA system plays an important role in tumor
cell adhesion and migration as well, treatments aimed at interfering
with the nonproteolytic properties of this multifactorial system may
also prove beneficial.
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